stroke

ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
AI-Based Stroke Rehab System Shown to Be as Effective as One-on-One Therapy
AI-Based Stroke Rehab System Shown to Be as Effective as One-on-One Therapy
Medical Devices and Diagnostics Industry
Motus Nova
theratainment
artificial intelligence
rehab
stroke
Flag link:
Pig brain tech could spur stroke therapies, drug and target validation
Pig brain tech could spur stroke therapies, drug and target validation
BioCentury
animal models
R&D
stroke
Flag link:
Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke
Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke
Fierce Biotech
Acticor
blood thinners
stroke
Flag link:
Microbiome Report for Week Ending 3/16/19
Microbiome Report for Week Ending 3/16/19
CP Wire
microbiome
Seres Therapeutics
AstraZeneca
stroke
Flag link:
Microbiome Report for Week Ending 3/16/19
microbiome
Seres Therapeutics
AstraZeneca
stroke
Flag link:
BioXyTran Files for $10 Million Offering to Advance Stroke and Wound Healing Candidates
BioXyTran Files for $10 Million Offering to Advance Stroke and Wound Healing Candidates
CP Wire
BioXyTran
stroke
Flag link:
11 innovative medical devices you need to know from 2018
11 innovative medical devices you need to know from 2018
Medical Design and Outsourcing
devices
Cerebrotech Visor
stroke
blood glucose monitoring
migraines
diagnostics
mobile apps
neurodegenerative disease
spectrometry
Flag link:
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears
Fierce Pharma
Sanofi
Lemtrada
FDA
stroke
MS
Flag link:
Death Rates From Heart Disease And Stroke Could Be Significantly Less With These Drugs, Study Says
Death Rates From Heart Disease And Stroke Could Be Significantly Less With These Drugs, Study Says
Forbes
ESC 2018
stroke
heart disease
calcium channel blockers
statins
Flag link:
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
CP Wire
IschemiaView
stroke
devices
RAPID platform
Flag link:
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
IschemiaView
stroke
Flag link:
Encouraging trial results for Daiichi anti-stroke therapy
Encouraging trial results for Daiichi anti-stroke therapy
The Pharma Letter
Daiichi Sankyo
Lixiana
edoxaban
clinical trials
atrial fibrilation
stroke
Flag link:
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
CP Wire
Bristol-Myers Squibb
Janssen
Factor XIa
stroke
Flag link:
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Bristol-Myers Squibb
Janssen
Factor XIa
stroke
Flag link:
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Fierce Pharma
Amgen
Repatha
DTC ads
heart attack
stroke
Flag link:
Biogen to Discontinue Development of Stroke Drug After Early-Stage Trial Failure
Biogen to Discontinue Development of Stroke Drug After Early-Stage Trial Failure
Xtalks
Biogen
stroke
clinical trials
natalizumab
Flag link:
In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed
In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed
Endpoints
Bayer
JNJ
stroke
clinical trials
Xarelto
bloodthinners
Flag link:
Details on surprise Novartis heart drug success due Aug 27
Details on surprise Novartis heart drug success due Aug 27
Yahoo/Reuters
Novartis
canakinumab
heart attacks
stroke
Flag link:
Why Amgen's Success Was a Big Disappointment
Why Amgen's Success Was a Big Disappointment
Motley Fool
Amgen
Repatha
heart attacks
stroke
Flag link:

Pages